Patents by Inventor Manuel Sepulveda

Manuel Sepulveda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240139265
    Abstract: The disclosure relates to prostate neoantigens, polynucleotides encoding them, vectors, host cells, recombinant virus particles, vaccines comprising the neoantigens, proteinaceous molecules binding the prostate neoantigens, and methods of making and using them.
    Type: Application
    Filed: June 27, 2023
    Publication date: May 2, 2024
    Inventors: Kurtis E. Bachman, Vipul Bhargava, Darryl L. Davis, Vinod Krishna, Guido Leoni, David Pocalyko, Pegah Safabakhsh, Manuel Sepulveda, Derick Siegel, Marco Gottardis
  • Patent number: 11932680
    Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 8, 2022
    Date of Patent: March 19, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Patent number: 11793843
    Abstract: The disclosure relates to prostate neoantigens, polynucleotides encoding them, vectors, host cells, recombinant virus particles, vaccines comprising the neoantigens, proteinaceous molecules binding the prostate neoantigens, and methods of making and using them.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: October 24, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Kurtis E. Bachman, Vipul Bhargava, Darryl L. Davis, Vinod Krishna, Guido Leoni, David Pocalyko, Pegah Safabakhsh, Manuel Sepulveda, Derick Siegel, Marco Gottardis
  • Publication number: 20230143550
    Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: March 8, 2022
    Publication date: May 11, 2023
    Inventors: Rebecca HAWKINS, Steven JACOBS, Manuel SEPULVEDA
  • Patent number: 11447539
    Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: September 20, 2022
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Publication number: 20220259289
    Abstract: FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: April 28, 2022
    Publication date: August 18, 2022
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Patent number: 11345739
    Abstract: FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: May 31, 2022
    Assignee: JANSSEN BIOTECH, INC
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Patent number: 11299534
    Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: April 12, 2022
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Publication number: 20210040180
    Abstract: FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: March 17, 2020
    Publication date: February 11, 2021
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Publication number: 20210032312
    Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: March 17, 2020
    Publication date: February 4, 2021
    Inventors: Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Publication number: 20210024612
    Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: February 26, 2020
    Publication date: January 28, 2021
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Publication number: 20200222478
    Abstract: The disclosure relates to prostate neoantigens, polynucleotides encoding them, vectors, host cells, recombinant virus particles, vaccines comprising the neoantigens, proteinaceous molecules binding the prostate neoantigens, and methods of making and using them.
    Type: Application
    Filed: January 9, 2020
    Publication date: July 16, 2020
    Inventors: Kurtis E. Bachman, Vipul Bhargava, Darryl L. Davis, Vinod Krishna, Guido Leoni, David Pocalyko, Pegah Safabakhsh, Manuel Sepulveda, Derick Siegel, Marco Gottardis
  • Patent number: 10626165
    Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: April 21, 2020
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Patent number: 10611823
    Abstract: FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: April 7, 2020
    Assignee: HANSSEN BIOTECH, INC
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Patent number: 10597438
    Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: March 24, 2020
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Publication number: 20180162929
    Abstract: FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: December 13, 2017
    Publication date: June 14, 2018
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Publication number: 20180162927
    Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: December 13, 2017
    Publication date: June 14, 2018
    Inventors: Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Publication number: 20180162928
    Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: December 13, 2017
    Publication date: June 14, 2018
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Publication number: 20150141735
    Abstract: The present invention relates to a method and device for the selective destruction of cells that with uncontrolled proliferation in an animal organism, with minimum damage to the surrounding tissue thereby and without needing to perform any kind of surgical operation on the patient: the method consists of the detection of the tumorous area (1) and the sequential and alternate application of at least two alternating magnetic fields with different directions to the treatment area or application until achieving the heating and destruction of the cells. The device used is, therefore, comprised of at least two electromagnets (11, 12) or at least two pairs of electromagnets (11-11?, 12-12?) all being located around the perimeter of a hypothetical circumference or sphere, with the electromagnets in opposing pairs where each opposing pair generates an electromagnetic field in one direction and orientation.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 21, 2015
    Applicant: INVESTIGACIONES, DESARROLLOS INNOVACIONES TAT IBERICA, S.L.
    Inventors: Ricardo Díaz Valle, Sonia Tejada Solís, Juan Manuel Sepúlveda Sánchez, Virginia Rodríguez González, Ana Castaños Cantos, Marina Torres Gómez, Ildefonso Del Campo Sánchez, Vicente Torres Junco
  • Publication number: 20150065007
    Abstract: Provided is a magnetic building block, in the form of a 3D polygon of non-magnetic material having at least four faces. The faces meet in sets of at least three to define at least four vertices and a generally enclosed structure, each face having an outer surface. At least one internal holder is adjacent to at least one vertex, each holder structured and arranged to receive a magnetic ball and permit free rotation of the magnetic ball. The holder positions the magnetic ball so as to be generally in about equal distance to the outer surface of at least three faces. A magnetic ball is disposed in each internal holder.
    Type: Application
    Filed: August 30, 2013
    Publication date: March 5, 2015
    Applicant: CubeCraft, LLC
    Inventors: Jeremy B. Klepper, Manuel Sepulveda